450
Views
1
CrossRef citations to date
0
Altmetric
Review

Evolution of antifungals for invasive mold infections in immunocompromised hosts, then and now

ORCID Icon, ORCID Icon & ORCID Icon
Pages 535-549 | Received 13 Mar 2023, Accepted 24 Apr 2023, Published online: 01 May 2023

References

  • Nnadi NE, Carter DA, Jabra-Rizk MA. Climate change and the emergence of fungal pathogens. PLOS Pathog. 2021;17:e1009503.
  • Berger S, El Chazli Y, Babu AF, et al. Azole resistance in aspergillus fumigatus: a consequence of antifungal use in agriculture? Front Microbiol. 2017;8:1024. DOI:10.3389/fmicb.2017.01024
  • Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, et al. Sixty years of amphotericin b: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther. 2021;10:115–147.
  • Al-Mohsen I, Hughes WT. Systemic antifungal therapy: past, present and future. Ann Saudi Med. 1998;18:28–38.
  • Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin North Am. 2016;30:51–83.
  • Kneale M, Bartholomew JS, Davies E, et al. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother. 2016;71:3599–3606.
  • Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(Suppl 1):1–10.
  • Maxfield L, Preuss CV, Bermudez R. Terbinafine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Oct 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545218/
  • Vazquez JA. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Clin Infect Dis. 2008;46:1889–1901.
  • Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142–1151.
  • Hüttel W. Echinocandins: structural diversity, biosynthesis, and development of antimycotics. Appl Microbiol Biotechnol. 2021;105:55–66.
  • Patterson TF, GR T 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–60. DOI:10.1093/cid/ciw326
  • Greer ND. Voriconazole: the newest triazole antifungal agent. Proc. 2003;16:241–248.
  • Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol. 1976;83:367–382.
  • Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-β-cydodextrin (SBECD) [Internet]. J Pharmaceut sci. Available from 2010;99:3291–3301. DOI:10.1002/jps.22109
  • Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209:1941–1948.
  • Tan I, Lomasney L, Stacy GS, et al. Spectrum of voriconazole-induced periostitis with review of the differential diagnosis. AJR Am J Roentgenol. 2019;212:157–165.
  • Park WB, Kim N-H, Kim K-H, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080–1087.
  • Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015;8:321–334.
  • Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
  • Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347.
  • Kraljevic M, Khanna N, Medinger M, et al. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021;59:701–711.
  • Chin A, Pergam SA, Fredricks DN, et al. Evaluation of posaconazole serum concentrations from delayed-release tablets in patients at high risk for fungal infections. Antimicrob Agents Chemother. InternetAvailable from 2017;61:61. DOI: 10.1128/AAC.00569-17
  • Van Matre ET, Evans SL, Mueller SW, et al. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center. Ann Clin Microbiol Antimicrob. 2019;18:13.
  • Burks C, Darby A, Gómez Londoño L, et al. Azole-resistant Aspergillus fumigatus in the environment: identifying key reservoirs and hotspots of antifungal resistance. PLOS Pathog. 2021;17:e1009711.
  • Wiederhold NP. Antifungal susceptibility testing: a primer for clinicians. Open Forum Infect Dis. 2021;8:ofab444. DOI:10.1093/ofid/ofab444
  • Lockhart SR, Ghannoum MA, Alexander BD. Establishment and use of epidemiological cutoff values for molds and yeasts by use of the clinical and laboratory standards institute M57 standard. J Clin Microbiol. 2017;55:1262–1268.
  • CLSI. Epidemiological cutoff values for antifungal susceptibility testing, M59Ed3E. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
  • Seyedmousavi S, Meletiadis J, Melchers WJG, et al. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57:796–803.
  • Campitelli M, Zeineddine N, Samaha G, et al. Combination antifungal therapy: a review of current data. J Clin Med Res. 2017;9:451–456.
  • Screening for triazole-resistant Aspergillus fumigatus using agar plates [Internet]. 2021 [cited 2022 Dec 15]. Available from: https://www.cdc.gov/fungal/lab-professionals/azole-resistant-aspergillus.html.
  • Pelzer BW, Seufert R, Koldehoff M, et al. Performance of the AsperGenius® PCR assay for detecting azole resistant Aspergillus fumigatus in BAL fluids from allogeneic HSCT recipients: a prospective cohort study from Essen, West Germany. Med Mycol. 2019;58:268–271.
  • Badali H, Wiederhold NP. Antifungal resistance testing and implications for management. Curr Fungal Infect Rep. 2019;13:274–283. 10.1007/s12281-019-00354-6
  • Latgé J-P, Chamilos G, Aspergillus fumigatus and Aspergillosis in 2019 [Internet]. Clinical Microbiology Reviews. 33: Available from. 2019; DOI:10.1128/cmr.00140-18
  • Der Linden JWM V, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49(Suppl 1):S82–89.
  • Egli A, Fuller J, Humar A, et al. Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis. Transplantation. 2012;94:403–410.
  • Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. InternetAvailable from 2010;48:3251–3257. DOI:10.1128/jcm.00536-10
  • Hagiwara D, Watanabe A, Kamei K, et al. Epidemiological and genomic landscape of azole resistance mechanisms in aspergillus fungi. Front Microbiol. 2016;7:1382.
  • Camargo JF, Jabr R, Anderson AD, et al. Successful treatment of disseminated disease due to highly resistant aspergillus calidoustus with a novel antifungal therapy. Antimicrob Agents Chemother. 2022;66:e0220621.
  • Steinbach WJ, DK B Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39:192–198.
  • Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new “gold standard. Clin Infect Dis. 2003;37:415–425.
  • Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am j med. 1994;97:135–144. DOI:10.1016/0002-9343(94)90023-X
  • Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415. DOI:10.1056/NEJMoa020191
  • Herbrecht R, Patterson TF, Slavin MA, et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis. 2015;60:713–720.
  • Patterson TF, Boucher HW, Herbrecht R, et al. Strategy Of following voriconazole versus amphotericin b therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome [Internet]. Clinl Infect Dis. Available from 2005;41:1448–1452. DOI:10.1086/497126
  • Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2–12. DOI:10.1086/508774
  • Maertens JA, II R, KA M, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769. DOI:10.1016/S0140-6736(15)01159-9
  • Herbrecht R, Kuessner D, Pooley N, et al. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis. Curr Med Res Opin. 2018;34:2187–2195.
  • Bellanger A-P, Berceanu A, Scherer E, et al. Invasive fungal disease, isavuconazole treatment failure, and death in acute myeloid leukemia patients. Emerg Infect Dis. 2019;25:1778–1779.
  • Fung M, Schwartz BS, Doernberg SB, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis. 2018;67:1142–1143.
  • Cheng MP, Orejas JL, Arbona-Haddad E, et al. Use of triazoles for the treatment of invasive aspergillosis: a three-year cohort analysis. Mycoses. 2020;63:58–64.
  • Maertens JA, Rahav G, Lee D-G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397:499–509. DOI:10.1016/S0140-6736(21)00219-1
  • Barde F, Billaud E, Goldwirt L, et al. Low central nervous system posaconazole concentrations during cerebral phaeohyphomycosis. Antimicrob Agents Chemother. 2019;63. InternetAvailable from. DOI:10.1128/AAC.01184-19
  • Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiload Trial) [Internet]. Clinl Infect Dis. Available from 2007;44:1289–1297. DOI:10.1086/514341
  • Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European organisation for research and treatment of cancer study. Bone Marrow Transplant. 2010;45:1227–1233.
  • Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64:1274–1281.
  • Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010;61:410–418.
  • Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337–349. DOI:10.1016/j.jinf.2006.03.003
  • Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563–1571.
  • Panackal AA. Combination antifungal therapy for invasive aspergillosis revisited. Med Mycol Open Access. InternetAvailable from. 2016. 2. DOI:10.21767/2471-8521.100012
  • Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2014;28:80–94. DOI:10.1016/j.ijid.2014.07.007
  • Wattier RL, Dvorak CC, Hoffman JA, et al. A prospective, international cohort study of invasive mold infections in children. J Pediatric Infect Dis Soc. 2015;4:313–322.
  • Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162:81–89. DOI:10.7326/M13-2508
  • II R, AE Z, GE H, et al. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45:283–288.
  • Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194:1008–1018.
  • Sugar AM. Antifungal combination therapy: where we stand. Drug Resist Updat. 1998;1:89–92.
  • Sugar AM. Overview: antifungal combination therapy. Curr Opin Invest Drugs. 2001;2:1364–1365.
  • Buil JB, Snelders E, Denardi LB, et al. Trends in azole resistance in aspergillus fumigatus, the Netherlands, 1994-2016. Emerg Infect Dis. 2019;25:176–178.
  • van Ingen J, van der Lee HAL, Rijs AJMM, et al. High-level pan-azole-resistant aspergillosis. J Clin Microbiol. 2015;53:2343–2345.
  • Heo ST, Tatara AM, Jiménez-Ortigosa C, et al. Changes In in vitro susceptibility patterns of aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center, 1999–2015. Clin Infect Dis. 2017;65:216–225.
  • Rivero-Menendez O, Soto-Debran JC, Cuenca-Estrella M, et al. In Vitro activity of ibrexafungerp against a collection of clinical isolates of aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies. J Fungi (Basel). 2021;7:232. DOI:10.3390/jof7030232
  • Open-label study of APX001 for treatment of patients with invasive mold infections caused by aspergillus or rare molds - full text view - ClinicalTrials.Gov [Internet]. [cited 2023 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT04240886.
  • Ghannoum M, Long L, Larkin EL, et al. Evaluation Of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis. Antimicrob Agents Chemother. 2018;62. InternetAvailable from. DOI:10.1128/AAC.00244-18
  • Rauseo AM, Coler-Reilly A, Larson L, et al. Hope on The horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020;7:ofaa016.
  • Maertens JA, Verweij PE, Lanuza EF, et al. 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32). Open Forum Infect Dis. 2022;9:ofac492.063.
  • Kline A, Lionakis MS. Case commentary: long-term fosmanogepix use in a transplant recipient with disseminated aspergillosis caused by azole-resistant aspergillus calidoustus. Antimicrob Agents Chemother. 2022;66:e0236821.
  • Nucci M, Garnica M, Gloria AB, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect. 2013;19:745–751.
  • Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl 3):27–46. DOI:10.1111/1469-0691.12465
  • Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90:999–1008.
  • Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704.
  • Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect. 2010;60:331–337.
  • Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446–4450.
  • Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315–319.
  • Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European confederation of medical mycology in cooperation with the international society for human and animal mycology and the American society for microbiology. Lancet Infect Dis. 2021;21:e246–257. DOI:10.1016/S1473-3099(20)30784-2
  • Nucci M, Jenks J, Thompson GR, et al. Do high MICs predict the outcome in invasive fusariosis? J Antimicrob Chemother. 2021;76:1063–1069.
  • Pérez-Nadales E, Alastruey-Izquierdo A, Linares-Sicilia MJ, et al. Invasive fusariosis in nonneutropenic patients, Spain, 2000-2015. Emerg Infect Dis. 2021;27:26–35.
  • Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less‐common, emerging, or refractory fungal infections [internet]. Clinl Infect Dis. Available from 2003;36:1122–1131. DOI:10.1086/374557
  • II R, RY H, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398–1403.
  • Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation. 2003;76:1632–1637.
  • Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365–1366.
  • Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2004;23:1059–1061.
  • Durand-Joly I, Alfandari S, Benchikh Z, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41:4898–4900.
  • Ho DY, Lee JD, Rosso F, et al. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses. 2007;50:227–231.
  • Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394–397.
  • Stempel JM, Hammond SP, Sutton DA, et al. Invasive fusariosis in the voriconazole era: single-center 13-year experience. Open Forum Infect Dis. 2015;2:ofv099.
  • Inano S, Kimura M, Iida J, et al. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review. J Infect Chemother. 2013;19:1173–1180.
  • Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81:1703–1729. DOI:10.1007/s40265-021-01611-0
  • Bhagavatula S, Vale L, Evans J, et al. Scedosporium prolificans osteomyelitis following penetrating injury: a case report. Med Mycol Case Rep. 2014;4:26–29.
  • Steinbach WJ, Schell WA, Miller JL, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41:3981–3985.
  • Kowacs PA, Soares Silvado CE, Monteiro de Almeida S, et al. Infection of the CNS by Scedosporium apiospermum after near drowning. Report of a fatal case and analysis of its confounding factors. J Clin Pathol. 2004;57:205–207.
  • Wiederhold NP, Gibas CFC. From the clinical mycology laboratory: new species and changes in fungal taxonomy and nomenclature. J Fungi (Basel). 2018;4:138. InternetAvailable from. DOI:10.3390/jof4040138
  • Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–1750.
  • Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–197.
  • Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis. 2014;16:578–587.
  • Seidel D, Meißner A, Lackner M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®. Crit Rev Microbiol. 2019;45:1–21.
  • Husain S, Munoz P, Forrest G, et al. Infections due to scedosporium apiospermum and scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome [Internet]. Clinl Infect Dis. 2005;89–99. Available from. DOI:10.1086/426445
  • Walsh TJ, Peter J, McGough DA, et al. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother. 1995;39:1361–1364.
  • Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 1998;42:282–288.
  • Cuenca-Estrella M, Ruiz-Díez B, Martínez-Suárez JV, et al. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 1999;43:149–151.
  • Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42:741–745.
  • Meletiadis J, Meis JFGM, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62–68.
  • Nomdedéu J, Brunet S, Martino R, et al. Successful treatment of pneumonia due to scedosporium apiospermum with itraconazole: case report. Clin Infect Dis. 1993;16:731–733.
  • Goldberg SL, Geha DJ, Marshall WF, et al. Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis. 1993;16:803–805.
  • Mellinghoff IK, Winston DJ, Mukwaya G, et al. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis. 2002;34:1648–1650.
  • Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother. 2001;45:2151–2153.
  • Jenks JD, Seidel D, Cornely OA, et al. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: analysis of patients in the FungiScope® registry. Mycoses. 2020;63:437–442.
  • Meletiadis J, Mouton JW, Rodriguez-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother. 2000;44:470–472.
  • Meletiadis J, Mouton JW, Meis JFGM, et al. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106–117.
  • Howden BP, Slavin MA, Schwarer AP, et al. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111–113.
  • Whyte M, Irving H, O’Regan P, et al. DISSEMINATED SCEDOSPORIUM PROLIFICANS INFECTION and SURVIVAL of a CHILD with ACUTE LYMPHOBLASTIC LEUKEMIA [Internet]. Pediatr Infect Dis J. Available from 2005;24:375–377. DOI:10.1097/01.inf.0000157213.94392.30
  • Bhat SV, Paterson DL, Rinaldi MG, et al. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis. 2007;39:87–90.
  • Guinea J, Peláez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, candida, aspergillus, fusarium, and scedosporium species. Antimicrob Agents Chemother. 2008;52:1396–1400.
  • Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2020;75:3582–3585.
  • Biswas C, Law D, Birch M, et al. In vitro activity of the novel antifungal compound F901318 against Australian scedosporium and lomentospora fungi. Med Mycol. 2018;56:1050–1054.
  • Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56:2635–2642.
  • Kirchhoff L, Dittmer S, Buer J, et al. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents. 2020;56:106105.
  • Wiederhold NP. Review of the novel investigational antifungal olorofim. J Fungi (Basel). 2020;6:122. InternetAvailable from. DOI:10.3390/jof6030122
  • Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res. 2021;10:507.
  • Gale GR, Welch AM. Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum. Am J Med Sci. 1961;241:604–612.
  • Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19:e405–421.
  • Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3:e543–552.
  • Husain S, Silveira FP, Azie N, et al. Epidemiological features of invasive mold infections among solid organ transplant recipients: pATH Alliance®registry analysis [Internet]. Med Mycol. 2016;myw086. Available from. DOI:10.1093/mmy/myw086
  • Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis. 2013;15:233–242.
  • Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective Surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clinl Infect Dis. Available from 2010;50:1091–1100. DOI:10.1086/651263
  • Freeman Weiss Z, Leon A, Koo S. The evolving landscape of fungal diagnostics, current and emerging microbiological approaches. J Fungi (Basel) 2021;7. InternetAvailable from. DOI:10.3390/jof7020127
  • Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French multicentre cohort study (2003-2008). Clin Microbiol Infect. 2012;18:E396–400.
  • Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order [Internet]. Antimicrob Agents Chemother. 2015;59:7735–7742. Available from. DOI:10.1128/aac.01919-15
  • Almyroudis NG, Sutton DA, Fothergill AW, et al. In Vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents [Internet]. Antimicrob Agents Chemother. Available from 2007;51:2587–2590. DOI: 10.1128/aac.00452-07
  • Lamoth F, Damonti L, Alexander BD. Role of antifungal susceptibility testing in non-aspergillus invasive mold infections. J Clin Microbiol. 2016;54:1638–1640. DOI:10.1128/JCM.00318-16
  • Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2011;67:715–722. DOI:10.1093/jac/dkr375
  • Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487–3496.
  • Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin b lipid complex and liposomal amphotericin b in a murine model of pulmonary mucormycosis [Internet]. Antimicrob Agents Chemother. Available from 2010;54:1298–1304. DOI:10.1128/aac.01222-09
  • Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70:3116–3123.
  • Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother. 2011;55:5018–5021.
  • Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837. DOI:10.1016/S1473-3099(16)00071-2
  • Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–371.
  • Klimko NN, Khostelidi SN, Volkova AG, et al. Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia. Mycoses. 2014;57(Suppl 3):91–96. DOI:10.1111/myc.12247
  • Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by mucorales, lomentospora prolificans and fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52:706–712.
  • Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22:811.e1–e811.e8.
  • Abidi MZ, Sohail MR, Cummins N, et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses. 2014;57:687–698.
  • Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–653.
  • Rodríguez MM, Pastor M, Javier Pastor F, et al. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against rhizopus microsporus in a murine disseminated infection [Internet]. Antimicrob Agents Chemother. Available from 2009;53:5022–5025. DOI:10.1128/aac.01026-09
  • Rodríguez MM, Pastor FJ, Sutton DA, et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother. 2010;54:1665–1669.
  • Miyazaki M, Horii T, Hata K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55:4652–4658.
  • Gebremariam T, Alkhazraji S, Alqarihi A, et al. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to rhizopus arrhizus. Antimicrob Agents Chemother. 2020;64. InternetAvailable from. DOI:10.1128/AAC.00178-20
  • Gebremariam T, Gu Y, Alkhazraji S, et al. LB1580. Efficacy assessment of MAT2203 encochleated oral formulation of amphotericin b, in the neutropenic mouse model of pulmonary mucormycosis. Open Forum Infect Dis. 2022;9(ofac492):1890. DOI:10.1093/ofid/ofac492.1890
  • Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European organization for research and treatment of cancer consensus criteria. Clin Infect Dis. 2008;47:674–683. DOI:10.1086/590566
  • Maertens JA, Thompson GR, Spec A, et al. 754. Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: interim results from a Phase 2b open-label study (NCT03583164, Study 32). Open Forum Infect Dis. 2022;9:ofac492.039.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.